Our mission is to pioneer the next wave of modern medicines to treat and cure the most significant diseases facing mankind today.
Although mankind has made dramatic advances in fighting disease to date, some of the deadliest afflictions remain uncured, including cancer and autoimmune disorders. Since its inception, the biotechnology industry has played a major role in developing new therapies. Even though the first wave of therapies has been effective, a new era of modern medicine is now emerging. Recent discoveries have provided insights into how we can better utilize the immune system to fight disease the way nature intended, and new advances in bioengineering have provided ways to leverage the immune system to our advantage. We believe understanding the complex interactions between molecules and cells will provide the key to the next generation of breakthrough therapies. The world of treatment possibilities abounds with this knowledge and we are positioned to translate these findings into new medicines to better the human condition.
CEO, DNA Medicine Institute; U.S Genomics; MD Harvard Medical School HST; AB Harvard.
Previously Cantor Fitzgerald, Needham, CRT, AQR, Citi. AB Brown University
SVP of Manufacturing and Operations
Previously Head of Manufacturing Ipsen; B.A. Boston University.
VP of Antibody Discovery
Previously Director of Biologics Research at Sanofi. Ph.D. from Rutgers University
SVP, Strategic Alliances
Previously VP of Global Business Development, Wuxi/HD Bioscience.
SVP, Head of Clinical Research & Development
Scientific Advisory Board
Bob Langer, Ph.D.
Institute Professor at MIT with over 840 written articles and over 500 issued or pending patents. Founder of AIR, Momenta, Acusphere, Tempo Pharma, others.
Laurie Glimcher, M.D.
President and CEO of Dana-Farber Cancer Institute; Professor, Harvard Medical School
Rita Colwell, Ph.D.
Chairman, Canon Life Sciences; Former Director NSF, appointed by Bill Clinton.
Ronald Levy, M.D.
Professor of Medicine, Director of the Lymphoma Program, Former Chief of the Division of Oncology at Stanford University.
Shiv Pillai, M.D., Ph.D.
Professor of Medicine, Harvard Medical School
Nai-Kong Cheung, M.D., Ph.D.
Head, Neuroblastoma Program; Enid A. Haupt Chair in Pediatric Oncology
George C. Tsokos
Professor of Medicine, Harvard Medical School. Chief, Rheumatology Division.